Published in Acta Neuropathol on October 28, 2004
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol (2010) 1.93
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell (2016) 1.74
Integrative analysis reveals the direct and indirect interactions between DNA copy number aberrations and gene expression changes. Bioinformatics (2008) 1.49
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol (2014) 1.12
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 1.04
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res (2014) 1.02
Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol (2012) 1.02
Targeted therapies for malignant glioma: progress and potential. BioDrugs (2009) 0.97
Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol (2012) 0.95
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res (2013) 0.92
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol (2011) 0.85
"MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management? J Mol Diagn (2008) 0.85
miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS. Oncotarget (2016) 0.84
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun (2013) 0.84
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol (2015) 0.83
Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget (2016) 0.82
R-RAS2 overexpression in tumors of the human central nervous system. Mol Cancer (2013) 0.79
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol (2016) 0.78
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget (2016) 0.77
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. Neuro Oncol (2012) 0.77
Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study. Mol Clin Oncol (2016) 0.75
RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget (2016) 0.75
Something old and something new about molecular diagnostics in gliomas. Surg Pathol Clin (2012) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain (2005) 2.37
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol (2007) 2.11
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology (2013) 1.98
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol (2005) 1.83
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol (2010) 1.65
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res (2005) 1.63
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res (2009) 1.61
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer (2011) 1.61
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 1.57
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol (2013) 1.50
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer (2004) 1.50
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer (2005) 1.48
Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol (2009) 1.46
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev (2010) 1.45
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 1.43
Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol (2014) 1.42
Molecular pathogenesis of meningiomas. J Neurooncol (2004) 1.42
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol Ther (2008) 1.41
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. Arch Neurol (2007) 1.38
Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol (2013) 1.37
Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer (2005) 1.36
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol (2015) 1.35
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer (2008) 1.33
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer (2010) 1.31
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol (2009) 1.30
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer (2002) 1.29
Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol (2004) 1.29
Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res (2011) 1.27
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst (2003) 1.25
Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer (2003) 1.23
18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med (2006) 1.22
Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res (2009) 1.19
Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res (2013) 1.17
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol (2015) 1.16
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol (2012) 1.15
Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol (2007) 1.15
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res (2010) 1.15
Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer (2002) 1.11
Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One (2007) 1.11
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med (2011) 1.10
Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst (2004) 1.09
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem (2012) 1.09
Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer (2011) 1.08
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res (2010) 1.07
Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia (2002) 1.07
Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging (2010) 1.06
5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien) (2011) 1.06
Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol (2002) 1.06
Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg (2005) 1.05
Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. Proc Natl Acad Sci U S A (2010) 1.05
MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro Oncol (2013) 1.04
Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. Carcinogenesis (2009) 1.03
Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med (2007) 1.03
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol (2014) 1.01
Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.99
Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol (2006) 0.99
Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst (2006) 0.98
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res (2004) 0.98
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol (2015) 0.97
MGMT promoter methylation in malignant gliomas. Target Oncol (2010) 0.97